{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:28:47Z","timestamp":1773012527235,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["R44AG059524"],"award-info":[{"award-number":["R44AG059524"]}]},{"name":"NIH","award":["R01DK121789"],"award-info":[{"award-number":["R01DK121789"]}]},{"name":"NIH","award":["K25HL1448837"],"award-info":[{"award-number":["K25HL1448837"]}]},{"DOI":"10.13039\/100011495","name":"Massachusetts Life Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011495","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Imaging"],"DOI":"10.1038\/s44303-025-00075-1","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:49:32Z","timestamp":1744163372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Manganese-based type I collagen-targeting MRI probe for in vivo imaging of liver fibrosis"],"prefix":"10.1038","volume":"3","author":[{"given":"Chunxiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"DeRoche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Pantazopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Rotile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himashinie","family":"Diyabalanage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Humblet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Caravan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"75_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516\u2013537 (2023).","journal-title":"J. Hepatol."},{"key":"75_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea, V. & Friedman, S. L. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6, 425\u2013456 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"75_CR3","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","volume":"134","author":"SL Friedman","year":"2008","unstructured":"Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655\u20131669 (2008).","journal-title":"Gastroenterology"},{"key":"75_CR4","doi-asserted-by":"publisher","unstructured":"Roehlen, N., Crouchet, E. & Baumert, T. F. Liver Fibrosis: mechanistic concepts and therapeutic perspectives. Cells https:\/\/doi.org\/10.3390\/cells9040875 (2020).","DOI":"10.3390\/cells9040875"},{"key":"75_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva, T. & Brenner, D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18, 151\u2013166 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"75_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI30542","volume":"117","author":"JP Iredale","year":"2007","unstructured":"Iredale, J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Investig. 117, 539\u2013548 (2007).","journal-title":"J. Clin. Investig."},{"key":"75_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","volume":"20","author":"Y Sumida","year":"2014","unstructured":"Sumida, Y., Nakajima, A. & Itoh, Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 475\u2013485 (2014).","journal-title":"World J. Gastroenterol."},{"key":"75_CR8","first-page":"67","volume":"41","author":"J Joseph","year":"2020","unstructured":"Joseph, J. Serum marker panels for predicting liver fibrosis\u2014an update. Clin. Biochem. Rev. 41, 67\u201373 (2020).","journal-title":"Clin. Biochem. Rev."},{"key":"75_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4137\/BMI.S10009","volume":"7","author":"T Liu","year":"2012","unstructured":"Liu, T., Wang, X., Karsdal, M. A., Leeming, D. J. & Genovese, F. Molecular serum markers of liver fibrosis. Biomark. Insights 7, 105\u2013117 (2012).","journal-title":"Biomark. Insights"},{"key":"75_CR10","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","volume":"127","author":"WM Rosenberg","year":"2004","unstructured":"Rosenberg, W. M. et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127, 1704\u20131713 (2004).","journal-title":"Gastroenterology"},{"key":"75_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jhep.2005.10.019","volume":"44","author":"J Parkes","year":"2006","unstructured":"Parkes, J., Guha, I. N., Roderick, P. & Rosenberg, W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J. Hepatol. 44, 462\u2013474 (2006).","journal-title":"J. Hepatol."},{"key":"75_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.29721","volume":"68","author":"ZM Younossi","year":"2018","unstructured":"Younossi, Z. M. et al. Diagnostic modalities for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and associated fibrosis. Hepatology 68, 349\u2013360 (2018).","journal-title":"Hepatology"},{"key":"75_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo, K. et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150, 626\u2013637.e627 (2016).","journal-title":"Gastroenterology"},{"key":"75_CR14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","volume":"152","author":"CC Park","year":"2017","unstructured":"Park, C. C. et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152, 598\u2013607.e592 (2017).","journal-title":"Gastroenterology"},{"key":"75_CR15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jhep.2013.06.026","volume":"59","author":"BC Fuchs","year":"2013","unstructured":"Fuchs, B. C. et al. Molecular MRI of collagen to diagnose and stage liver fibrosis. J. Hepatol. 59, 992\u2013998 (2013).","journal-title":"J. Hepatol."},{"key":"75_CR16","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2017170595","author":"CT Farrar","year":"2018","unstructured":"Farrar, C. T. et al. CM-101: type I collagen-targeted MR imaging probe for detection of liver fibrosis. Radiology https:\/\/doi.org\/10.1148\/radiol.2017170595 (2018).","journal-title":"Radiology"},{"key":"75_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/hep4.1193","volume":"2","author":"DJ Erstad","year":"2018","unstructured":"Erstad, D. J. et al. Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. Hepatol. Commun. 2, 821\u2013835 (2018).","journal-title":"Hepatol. Commun."},{"key":"75_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/hep.28930","volume":"65","author":"B Zhu","year":"2017","unstructured":"Zhu, B. et al. Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model. Hepatology 65, 1015\u20131025 (2017).","journal-title":"Hepatology"},{"key":"75_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/ndt\/gfn593","volume":"24","author":"R Agarwal","year":"2009","unstructured":"Agarwal, R. et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol. Dial. Transpl. 24, 856\u2013863 (2009).","journal-title":"Nephrol. Dial. Transpl."},{"key":"75_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/sj.ki.5002338","volume":"72","author":"T Grobner","year":"2007","unstructured":"Grobner, T. & Prischl, F. C. Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 72, 260\u2013264 (2007).","journal-title":"Kidney Int."},{"key":"75_CR21","unstructured":"FDA. FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body (2017)."},{"key":"75_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1148\/radiol.2020192579","volume":"297","author":"Y Choi","year":"2020","unstructured":"Choi, Y. et al. MRI and quantitative magnetic susceptibility maps of the brain after serial administration of gadobutrol: a longitudinal follow-up study. Radiology 297, 143\u2013150 (2020).","journal-title":"Radiology"},{"key":"75_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1039\/C8MT00302E","volume":"11","author":"M Le Fur","year":"2019","unstructured":"Le Fur, M. & Caravan, P. The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. Metallomics 11, 240\u2013254 (2019).","journal-title":"Metallomics"},{"key":"75_CR24","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.1002\/anie.200700700","volume":"46","author":"P Caravan","year":"2007","unstructured":"Caravan, P. et al. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew. Chem. 46, 8171\u20138173 (2007).","journal-title":"Angew. Chem."},{"key":"75_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-020-02451-y","volume":"16","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMC Vet. Res. 16, 242 (2020).","journal-title":"BMC Vet. Res."},{"key":"75_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1162\/153535003322556877","volume":"2","author":"AM Loening","year":"2003","unstructured":"Loening, A. M. & Gambhir, S. S. AMIDE: a free software tool for multimodality medical image analysis. Mol. Imaging 2, 131\u2013137 (2003).","journal-title":"Mol. Imaging"},{"key":"75_CR27","doi-asserted-by":"publisher","unstructured":"Chen, H. H. et al. Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.91506 (2017).","DOI":"10.1172\/jci.insight.91506"},{"key":"75_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1148\/radiol.2020192118","volume":"296","author":"IY Zhou","year":"2020","unstructured":"Zhou, I. Y. et al. Advanced MRI of liver fibrosis and treatment response in a rat model of nonalcoholic steatohepatitis. Radiology 296, 67\u201375 (2020).","journal-title":"Radiology"},{"key":"75_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq6297","volume":"14","author":"Y Ning","year":"2022","unstructured":"Ning, Y. et al. Molecular MRI quantification of extracellular aldehyde pairs for early detection of liver fibrogenesis and response to treatment. Sci. Transl. Med. 14, eabq6297 (2022).","journal-title":"Sci. Transl. Med."},{"key":"75_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S1570-0232(03)00248-4","volume":"791","author":"PR Hutson","year":"2003","unstructured":"Hutson, P. R., Crawford, M. E. & Sorkness, R. L. Liquid chromatographic determination of hydroxyproline in tissue samples. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 791, 427\u2013430 (2003).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"75_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220036120","volume":"120","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T(1)-weighted MRI. Proc. Natl. Acad. Sci. USA 120, e2220036120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75_CR32","doi-asserted-by":"publisher","first-page":"10065","DOI":"10.1021\/ic300832e","volume":"51","author":"FK K\u00e1lm\u00e1n","year":"2012","unstructured":"K\u00e1lm\u00e1n, F. K. & Tircs\u00f3, G. Kinetic inertness of the Mn complexes formed with AAZTA and some open-chain EDTA derivatives. Inorg. Chem. 51, 10065\u201310067 (2012).","journal-title":"Inorg. Chem."},{"key":"75_CR33","doi-asserted-by":"publisher","first-page":"15548","DOI":"10.1021\/jacs.5b10748","volume":"137","author":"EM Gale","year":"2015","unstructured":"Gale, E. M., Atanasova, I., Blasi, F., Ay, I. & Caravan, P. A manganese alternative to gadolinium for MRI contrast. J. Am. Chem. Soc. 137, 15548\u201315557 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"75_CR34","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1021\/acs.jmedchem.2c01561","volume":"66","author":"SW McRae","year":"2023","unstructured":"McRae, S. W. et al. Development of a suite of gadolinium-free OATP1-targeted paramagnetic probes for liver MRI. J. Med. Chem. 66, 6567\u20136576 (2023).","journal-title":"J. Med. Chem."},{"key":"75_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/RLI.0000000000000736","volume":"56","author":"IY Zhou","year":"2021","unstructured":"Zhou, I. Y. et al. Positron emission tomography-magnetic resonance imaging pharmacokinetics, in vivo biodistribution, and whole-body elimination of Mn-PyC3A. Investig. Radiol. 56, 261\u2013270 (2021).","journal-title":"Investig. Radiol."},{"key":"75_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/RLI.0000000000000593","volume":"54","author":"DJ Erstad","year":"2019","unstructured":"Erstad, D. J. et al. Tumor contrast enhancement and whole-body elimination of the manganese-based magnetic resonance imaging contrast agent Mn-PyC3A. Investig. Radiol. 54, 697\u2013703 (2019).","journal-title":"Investig. Radiol."},{"key":"75_CR37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1148\/radiol.2017170977","volume":"286","author":"EM Gale","year":"2018","unstructured":"Gale, E. M. et al. A manganese-based alternative to gadolinium: contrast enhanced MR angiography, pharmacokinetics, and metabolism. Radiology 286, 865\u2013872 (2018).","journal-title":"Radiology"},{"key":"75_CR38","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1002\/mrm.28664","volume":"85","author":"J Xie","year":"2021","unstructured":"Xie, J. et al. Iron(III)-tCDTA derivatives as MRI contrast agents: increased T(1) relaxivities at higher magnetic field strength and pH sensing. Magn. Reson. Med. 85, 3370\u20133382 (2021).","journal-title":"Magn. Reson. Med."},{"key":"75_CR39","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1148\/radiol.2473070975","volume":"247","author":"PA Helm","year":"2008","unstructured":"Helm, P. A. et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology 247, 788\u2013796 (2008).","journal-title":"Radiology"},{"key":"75_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2012.04.035","volume":"57","author":"M Polasek","year":"2012","unstructured":"Polasek, M. et al. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J. Hepatol. 57, 549\u2013555 (2012).","journal-title":"J. Hepatol."},{"key":"75_CR41","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1165\/rcmb.2013-0039OC","volume":"49","author":"P Caravan","year":"2013","unstructured":"Caravan, P. et al. Molecular magnetic resonance imaging of pulmonary fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 49, 1120\u20131126 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"75_CR42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jhep.2015.04.029","volume":"63","author":"CT Farrar","year":"2015","unstructured":"Farrar, C. T. et al. 3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. J. Hepatol. 63, 689\u2013696 (2015).","journal-title":"J. Hepatol."},{"key":"75_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08838-6","volume":"7","author":"M Polasek","year":"2017","unstructured":"Polasek, M. et al. Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. Sci. Rep. 7, 8114 (2017).","journal-title":"Sci. Rep."},{"key":"75_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuro.2010.10.002","volume":"32","author":"W Zheng","year":"2011","unstructured":"Zheng, W., Fu, S. X., Dydak, U. & Cowan, D. M. Biomarkers of manganese intoxication. Neurotoxicology 32, 1\u20138 (2011).","journal-title":"Neurotoxicology"},{"key":"75_CR45","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1172\/JCI74368","volume":"124","author":"VJ Thannickal","year":"2014","unstructured":"Thannickal, V. J., Zhou, Y., Gaggar, A. & Duncan, S. R. Fibrosis: ultimate and proximate causes. J. Clin. Investig. 124, 4673\u20134677 (2014).","journal-title":"J. Clin. Investig."},{"key":"75_CR46","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","volume":"64","author":"YA Lee","year":"2015","unstructured":"Lee, Y. A., Wallace, M. C. & Friedman, S. L. Pathobiology of liver fibrosis: a translational success story. Gut 64, 830\u2013841 (2015).","journal-title":"Gut"},{"key":"75_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hep.21347","volume":"44","author":"R Williams","year":"2006","unstructured":"Williams, R. Global challenges in liver disease. Hepatology 44, 521\u2013526 (2006).","journal-title":"Hepatology"},{"key":"75_CR48","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.3350\/cmh.2022.0348","volume":"29","author":"T Reinson","year":"2023","unstructured":"Reinson, T., Buchanan, R. M. & Byrne, C. D. Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future. Clin. Mol. Hepatol. 29, S157\u2013S170 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"75_CR49","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.inorgchem.0c00510","volume":"59","author":"A Gupta","year":"2020","unstructured":"Gupta, A., Caravan, P., Price, W. S., Platas-Iglesias, C. & Gale, E. M. Applications for transition-metal chemistry in contrast-enhanced magnetic resonance imaging. Inorg. Chem. 59, 6648\u20136678 (2020).","journal-title":"Inorg. Chem."},{"key":"75_CR50","first-page":"638","volume":"38","author":"EJ Rummeny","year":"1997","unstructured":"Rummeny, E. J. et al. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies. Acta Radiol. 38, 638\u2013642 (1997).","journal-title":"Acta Radiol."},{"key":"75_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1148\/radiology.182.1.1309218","volume":"182","author":"B Hamm","year":"1992","unstructured":"Hamm, B. et al. Focal liver lesions: MR imaging with Mn-DPDP\u2013initial clinical results in 40 patients. Radiology 182, 167\u2013174 (1992).","journal-title":"Radiology"},{"key":"75_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/02841859709172407","volume":"38","author":"P Jynge","year":"1997","unstructured":"Jynge, P. et al. Cardiovascular safety of MnDPDP and MnCl2. Acta Radiol. 38, 740\u2013749 (1997).","journal-title":"Acta Radiol."},{"key":"75_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/RLI.0000000000001037","volume":"59","author":"VM Runge","year":"2024","unstructured":"Runge, V. M. & Heverhagen, J. T. A new era in magnetic resonance contrast media. Investig. Radiol. 59, 105\u2013107 (2024).","journal-title":"Investig. Radiol."},{"key":"75_CR54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/RLI.0000000000001053","volume":"59","author":"P Caravan","year":"2024","unstructured":"Caravan, P. Divalent manganese complexes as potential replacements for gadolinium-based contrast agents. Investig. Radiol. 59, 187\u2013196 (2024).","journal-title":"Investig. Radiol."},{"key":"75_CR55","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/01.rli.0000077057.88108.3f","volume":"38","author":"P Storey","year":"2003","unstructured":"Storey, P. et al. Preliminary evaluation of EVP 1001-1: a new cardiac-specific magnetic resonance contrast agent with kinetics suitable for steady-state imaging of the ischemic heart. Investig. Radiol. 38, 642\u2013652 (2003).","journal-title":"Investig. Radiol."},{"key":"75_CR56","doi-asserted-by":"publisher","first-page":"P3-04-03","DOI":"10.1158\/1538-7445.SABCS22-P3-04-03","volume":"83","author":"F W\u00e4rnberg","year":"2023","unstructured":"W\u00e4rnberg, F. et al. Abstract P3-04-03: safety, tolerability, and efficacy of the novel intravenous manganese-based contrast agent SN132D in patients with breast cancer: initial results of a phase I, first-in-human clinical trial SPAGOPIX-01. Cancer Res. 83, P3-04-03\u2013P03-04-03 (2023).","journal-title":"Cancer Res."},{"key":"75_CR57","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/RLI.0000000000001042","volume":"59","author":"TB Brismar","year":"2024","unstructured":"Brismar, T. B. et al. Oral Manganese chloride tetrahydrate: a novel magnetic resonance liver imaging agent for patients with renal impairment: efficacy, safety, and clinical implication. Investig. Radiol. 59, 197\u2013205 (2024).","journal-title":"Investig. Radiol."},{"key":"75_CR58","doi-asserted-by":"publisher","unstructured":"Sayaf, K. et al. Sex drives functional changes in the progression and regression of liver fibrosis. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms242216452 (2023).","DOI":"10.3390\/ijms242216452"}],"updated-by":[{"DOI":"10.1038\/s44303-025-00122-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000}}],"container-title":["npj Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44303-025-00075-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44303-025-00075-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44303-025-00075-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:09:20Z","timestamp":1761847760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44303-025-00075-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1038\/s44303-025-00075-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5349052\/v1","asserted-by":"object"}]},"ISSN":["2948-197X"],"issn-type":[{"value":"2948-197X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s44303-025-00122-x","URL":"https:\/\/doi.org\/10.1038\/s44303-025-00122-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M.G. holds equity in Reveal Pharmaceuticals and serves as a consultant to both Reveal Pharmaceuticals and Collagen Medical LLC. V.H. is an employee of Collagen Medical LLC. P.C. holds equity in, and is a consultant to, Collagen Medical LLC; holds equity in Reveal Pharmaceuticals Inc.; and receives research support from Pliant Therapeutics, Canon Medical USA, and Transcode Therapeutics. I.Y.Z. receives research support from Reveal Pharmaceuticals Inc. and currently serves as an Associate Editor of npj Imaging but was not involved in the editorial review of or the decision to publish this article. The other authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}